Clinical Trial Update: A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 dose-escalation study of the investigational KRAS inhibitor KST-6051 in adults with KRAS-mutant advanced solid tu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• KST-6051

Snippet

Sponsor: Kestrel Therapeutics, Inc. | Conditions: KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | Status: RECRUITING